Vosevi Dosage

Generic name: SOFOSBUVIR 400mg, VELPATASVIR 100mg, VOXILAPREVIR 100mg
Dosage form: tablet, film coated
Drug class: Antiviral combinations

Medically reviewed by Drugs.com. Last updated on Mar 14, 2024.

Testing Prior to the Initiation of Therapy

Test all patients for evidence of current or prior HBV infection by measuring hepatitis B surface antigen (HBsAg) and hepatitis B core antibody (anti-HBc) before initiating HCV treatment with VOSEVI.

Recommended Dosage

The recommended dosage of VOSEVI is one tablet, taken orally, once daily with food. One tablet of VOSEVI contains 400 mg of sofosbuvir, 100 mg of velpatasvir, and 100 mg of voxilaprevir. Table 1 shows the recommended treatment regimen and duration based on patient population.

Table 1 Recommended Treatment Regimen and Duration in Adults Without Cirrhosis or With Compensated Cirrhosis (Child-Pugh A)
Genotype	Patients Previously Treated with an HCV Regimen Containing:	VOSEVI Duration
* In clinical trials, prior NS5A inhibitor experience included daclatasvir, elbasvir, ledipasvir, ombitasvir, or velpatasvir. † In clinical trials, prior treatment experience included sofosbuvir with or without any of the following: peginterferon alfa/ribavirin, ribavirin, HCV NS3/4A protease inhibitor (boceprevir, simeprevir, or telaprevir).
1, 2, 3, 4, 5, or 6	An NS5A inhibitor*	12 weeks
1a or 3	Sofosbuvir without an NS5A inhibitor†	12 weeks

Renal Impairment

No dosage adjustment of VOSEVI is recommended in patients with any degree of renal impairment including patients on dialysis.

Moderate or Severe Hepatic Impairment

VOSEVI is not recommended in patients with moderate or severe hepatic impairment (Child-Pugh B or C) due to higher exposures of voxilaprevir in these patients.